B-cell Maturation Antigen (BCMA) Targeted Therapies Market – Increasing Number of Multiple Myeloma is expected to the Boost Growth of the Market
Overview:
Multiple myeloma (MM) is a type of blood cancer. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Plasma cells are an important part of the immune system, helping to fight a variety of infections and diseases. MM is a type of blood cancer and characterized by renal failure, low blood counts, hypercalcemia, monoclonal gammopathy, immune suppression, and anemia. Moreover, it remains an incurable disease. As reported by the American Cancer Society, in 2017, more than 30,280 new cases of multiple myeloma will be diagnosed in the United States and over 12,590 people will die from the disease. Furthermore, as reported by the National Center for Biotechnology Information (NCBI), MM represented 8.2% of all blood cancers in 2014 in Africa.
Get PDF Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/190
B-cell maturation antigen (BCMA) has become an important therapeutic target in MM. The expression profiles displayed by Transmembrane Activator and CAML Interactor (TACI) and BAFF-receptor (BAFF-R) are comparatively lower than those of BCMA in people with MM. Moreover, these antigens are rarely detected in malignant plasma cells, thus BCMA is preferred as a standard alternative over other antigens. Therefore, BCMA-targeted therapies have gained traction for cancer treatment and is the choice of treatment for MM. BCMA is an important therapeutic target in MM with three modalities of treatment in development, such as bispecific T-cell engagers (BITEs), antibody-drug conjugates (ADCs), and chimeric antigen receptor T-cell therapies (CAR T-cell therapies).
Drivers:
Increasing number of recurring cases of MM across the world is expected to augment growth of the global B-cell maturation Antigen (BCMA) targeted therapies market during the forecast period. Patients undergoing radiation therapy and chemotherapy are at higher risk of cancer recurrence because they develop resistance to these therapy. At this time, there is no cure for recurrent cancer and therefore BCMA targeted therapies provide successful therapeutic options for the treatment of recurrent MM.
Moreover, market players are focusing on developing and launching novel therapies (such as BITEs, ADCs, and CAR T-cell therapies), which in turn is drive to accelerate the global B-cell maturation Antigen (BCMA) targeted therapies market growth. For instance, GlaxoSmithKline Plc., in November 2017, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for GSK2857916 monotherapy in patients with multiple myeloma who have failed at least three prior lines of therapy, including an anti-CD38 antibody and are refractory to a proteasome inhibitor and an immunomodulatory agent.
